Feature | May 13, 2014

Elixir Receives European Approval for Fully Bioresorbable Novolimus-eluting Coronary Stent

Dramatically thinner scaffold combines excellent deliverability and conformability with DESolve’s market-leading clinical benefits

Elixir Medical Corp. DESolve 100 CE mark

May 13, 2014 — Elixir Medical Corp. received European CE mark approval for its DESolve 100 Novolimus-eluting Bioresorbable Coronary Scaffold System. The world’s first scaffold with a dramatically thinner strut profile of 100 microns is designed to degrade within one year, returning the patients’ coronary vessel ultimately to its normal de novo state while providing market-leading deliverability and conformability. DESolve 100 is designed to make scaffolds more user-friendly, enabling cardiologists to address the needs of a broader patient population. 

Like the DESolve scaffold, DESolve 100 is developed from the same proprietary poly-L Lactide (PLLA)-based material that provides optimal strength and support to the artery while delivering the novel anti-proliferative drug, Novolimus. The attributes of the DESolve family of scaffolds include (a) the ability to self-appose to the nominal vessel wall size in cases of mal-apposition; (b) the ability to maintain radial strength and vessel support for the necessary period of vessel healing while degrading within a year; and (c) the ability to have a wide margin of expansion.

“Elixir’s DESolve scaffold is already transforming the treatment of patients with coronary artery disease by providing the optimal vessel support while degrading in about a year leaving the vessel free of a permanent metallic implant,” said Stefan Verheye, M.D., Ph.D., ZNA Middleheim Hospital, Antwerp, Belgium, who treated the first patient with DESolve 100. “The CE mark approval for the breakthrough DESolve 100 scaffold builds on the clinically-proven success of DESolve.”

A total of 126 patients were enrolled at 13 centers in Europe, Brazil and New Zealand in the DESolve Nx pivotal trial, which evaluated the DESolve scaffold system. In addition to quantitative coronary angiography (QCA) follow-up on all patients, a subset of 46 patients underwent intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging at baseline and six-month follow-up, demonstrating excellent results. Subsequently, at one year, the DESolve Nx trial demonstrated a low MACE (major adverse cardiac events) rate of 5.69 percent with no definite scaffold thrombosis. Moreover, results using MSCT (multi slice coherence tomography), a noninvasive imaging modality to visualize coronary arteries and the manifestations of coronary artery disease, demonstrated a mean lumen area of 5.5 ± 2.2 mm2 at one year, maintaining the results that were observed at six months using other imaging modalities.

To support the international commercialization and reimbursement of DESolve 100, Elixir has announced a post-approval clinical study of 100 patients with sites in Brazil and Europe. In addition to QCA follow-up on all patients, a subset of patients will undergo IVUS and OCT imaging at baseline and six-month follow-up. All patients will be followed up at one year with annual clinical follow-ups through five years. DESolve 100 will be available in sizes ranging from 2.5 to 3.5 mm. Commercial launch is planned for 2015.

For more information: www.elixirmedical.com



Related Content

Synergy stent
Technology | October 05, 2015
October 5, 2015 — The U.S.
CeloNova BioSciences, Cobra PzF coronary stent system, second randomized trial, COBRA-REDUCE

Cobra PzF coronary stent system image courtesy of CeloNova BioSciences Inc.

News | Stents| September 23, 2015
CeloNova BioSciences Inc. announced that it has received conditional approval to start an investigational device...
ABSORB STEMI TROFI II trial, ESC 2015, bioresorbable vascular scaffold, BVS, STEMI patients

Image courtesy of Abbott Vascular

Feature | Stents Bioresorbable| September 04, 2015
A drug-eluting coronary stent made of absorbable material performed similarly to gold-standard metal among patients...
Absorb, BVS, bioresorbable stent
News | Stents Bioresorbable| September 01, 2015
September 1, 2015 — A bioresorbable drug-eluting coronary stent showed similar efficacy and safety results compared t
Stent graft, computational fluid dynamics, CFD, stent engineering

In this vector velocity model, brighter colors indicate blood flow acceleration as it passes through a bifurcation. Computation fluid dynamic modeling provides insight on blood flow through and near the walls of the stent graft. Image courtesy of Sanford Health

News | Cath Lab| August 27, 2015
August 27, 2015 — The use of computational fluid dynamics (CFD) modeling has been used for years to better engineer l
News | Cath Lab| August 26, 2015
August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report in
global interventional cardiology devices market, worth, Grand View Research, stents, catheters
News | Cath Lab| August 17, 2015
The global interventional cardiology devices market is expected to reach $25.16 billion by 2020, according to a new...
bioabsorbable scaffolds, BAS, global market, 2021, 10MM, 5EU, GlobalData

Absorb BVS image courtesy of Abbott

News | Stents Bioresorbable| August 05, 2015
The global market value for bioabsorbable scaffolds (BAS) will expand rapidly from $143.7 million in 2014 to just under...
European interventional cardiology market, drug-eluting stents, Abbott Laboratories, Boston Scientific, Medtronic

Boston Scientific's Eluvia drug-eluting vascular stent system. Image courtesy of Boston Scientific.

Feature | Stents| July 31, 2015
According to a new report on the Europe market for interventional cardiology by iData Research, drug-eluting stents...
Boston Scientific, fully absorbable scaffold, FAST study, resorbable
Feature | Stents Bioresorbable| July 20, 2015
Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully...
Overlay Init